Enveric Biosciences Inc (ENVB) News

Form 8-K - Current report

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Revealed seven classes of promising novel drug candidates discovered using Enveric’s Psybrary™ and PsyAI™ drug discovery and artificial...

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact...

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Biotechnology licensee expected to progress methods targeting breast and other cancers using cannabinoids in combination with chemotherapeutic...

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing...

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Second biotechnology company to potentially out-license novel compounds from Enveric’s portfolio of assets with possible significant milestone...

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Patents extend compositional protection to proprietary compounds Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 8-K - Current report

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. Enveric...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Enveric continues focused investment advancing novel neuroplastogenic molecules for the treatment of mental health disorders Enveric Biosciences...